Advance Search
WANG Daofeng, FU Jun, FANG Sanyou. Effect observation of bevacizumab combined with DDP chemotherapy in treatment of patients with non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2020, 24(22): 5-9. DOI: 10.7619/jcmp.202022002
Citation: WANG Daofeng, FU Jun, FANG Sanyou. Effect observation of bevacizumab combined with DDP chemotherapy in treatment of patients with non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2020, 24(22): 5-9. DOI: 10.7619/jcmp.202022002
shu

Effect observation of bevacizumab combined with DDP chemotherapy in treatment of patients with non-small cell lung cancer

  • Department of Respiratory Medicine, Taixing People's Hospital in Jiangsu Province, Taixing, Jiangsu, 225400

More Information
  • Received Date: September 11, 2020
  • Available Online: December 21, 2020
  • Published Date: December 02, 2020
    Graphical Abstract
    • Abstract
  • Objective To observe the effect of bevacizumab combined with DDP chemotherapy(cisplatin plus docetaxel)on the levels of serum vascular endothelial growth factor(VEGF), hypoxia-inducible factor-1α(HIF-1α)and stromal cell-derived factor-1α(SDF-1α)in patients with non-small cell lung cancer(NSCLC). Methods Totally 64 patients with NSCLC were randomly divided into two groups, with 32 cases in each group. Control group was treated with DDP chemotherapy, while observation group was treated with bevacizumab on the basis of the control group. Clinical efficacy, incidence of toxic and side effects, levels of serum VEGF-A, VEGF-B, VEGF-C, carbohydrate antigen 19-9(CA199), carcinoembryonic antigen(CEA), cytokeratin 19 fragment(CYFRA21-1)and expressions of mRNA of HIF-1α and SDF-1α before and after treatment were compared between two groups. The survival rates at 6, 12 and 24 months of follow-up were compared between the two groups. Results The objective response rate and disease control rate in the observation group were significantly higher than those in the control group(P<0.05). After treatment, the levels of serum VEGF-A, VEGF-B, VEGF-C, CA199, CEA, CYFRA21-1 and the expressions of mRNA of HIF-1α and SDF-1α in the observation group were significantly lower than those in the control group(P<0.05). There was no significant difference in incidence of toxic and side effects between two groups(P>0.05). At 24 months of follow-up, the survival rate of the observation group was significantly higher than that of the control group(P<0.05). Conclusion Bevacizumab combined with DDP chemotherapy can significantly reduce the serum levels of VEGF, CA199, CEA and CYFRA21-1, inhibit - the expressions of HIF-1α and SDF-1α, increase the therapeutic effect and survival rate, and has higher safety.
    • FullText(HTML)
    • References (28)
  • MICHA J P, SASSOON A F, WONG H, et al. Prolonged remission of recurrent cervical carc-inoma following paclitaxel and carboplatin chemotherapy with paclitaxel maintenance che-motherapy[J]. Anticancer Drugs, 2015, 26(7): 793-796.
    HERBST R S, BAAS P, KIM D W, et al. Pembrolizumab versus docetaxel for previously treate-d, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550.
    曹恒, 王静, 纪媛媛, 等. 甲磺酸阿帕替尼治疗晚期非小细胞肺癌临床观察[J]. 中华肿瘤防治杂志, 2017, 24(7): 468-471.
    郭卫东. 探析DC-CIK联合化疗治疗晚期非小细胞肺癌的临床效果[J]. 中华肿瘤防治杂志, 2016, 23(5): 335-336.
    陈刚, 邬冬强. 贝伐珠单抗注射液辅助治疗老年局部非小细胞肺癌的临床研究[J]. 中国临床药理学杂志, 2016, 32(21): 1967-1970.
    LI F, CHEN G, JIAO S. Bevacizumab Combined with Chemotherapy as First-line Therapy for Advanced Non-Small Cell Lung Cancer: A Retrospective Study[J]. Hepatogastroenterology, 2015, 62(140): 797-801.
    陈孝平, 汪建平. 外科学[M]. 8版. 北京: 人民卫生出版社, 2013: 282-288.
    张雅军, 徐锋, 韩纪昌, 等. 培美曲塞联合紫杉醇和顺铂治疗非小细胞肺癌的临床研究[J]. 中国临床药理学杂志, 2016, 32(15): 1396-1399.
    王玲, 邹潇, 刘辉国, 等. Testin在非小细胞肺癌组织和细胞株中的表达及其对癌细胞恶性生物学行为的影响[J]. 中国肿瘤生物治疗杂志, 2017, 24(9): 984-989.
    CHINO H, AMANO Y, YAMAUCHI Y, et al. Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer[J]. J Thorac Dis, 2016, 8(9): 2646-2650.
    邢若, 王鹏, 刘玉豪. 贝伐珠单抗辅助常规化疗治疗非小细胞肺癌的临床研究[J]. 中国临床药理学杂志, 2019, 35(1): 17-19.
    文峰, 向燕, 王少龙. 厄洛替尼联合艾迪注射液在非小细胞肺癌中应用对患者肿瘤标志物及免疫功能的影响[J]. 海南医学院学报, 2018, 24(9): 56-59.
    徐萍, 李红梅. 贝伐珠单抗在非小细胞肺癌中的应用进展[J]. 中国肺癌杂志, 2017, 20(4): 272-277.
    陶虹, 郭丽丽, 吴洪波, 等. 贝伐珠单抗联合化疗对复治晚期非鳞非小细胞肺癌患者的疗效及预后分析[J]. 中国肿瘤临床, 2018, 45(10): 503-507.
    潘雷, 殷俊, 傅文凡, 等. 过表达hsa-miR-202对非小细胞肺癌顺铂耐药细胞生物学行为的影响[J]. 山东医药, 2018, 58(8): 18-21.
    崔超, 史丽霞, 李淼, 等. 多西紫杉醇或紫杉醇联合顺铂治疗老年晚期非小细胞肺癌的疗效比较[J]. 中国老年学杂志, 2017, 37(23): 5867-5869.
    朱明珍, 徐海燕, 蒋华. 晚期非小细胞肺癌HIF-1α、ERCC1基因多态性与铂类药物疗效的关系[J]. 实用医学杂志, 2016, 32(3): 385-388.
    杨庆珣, 梁有卓. 非小细胞肺癌中间质细胞衍生因子-1及神经生长因子的表达及其临床意义[J]. 中国医学创新, 2017, 14(9): 33-36.
    汪硕敏, 顾康生. 血清癌胚抗原、铁蛋白和糖类抗原199在非小细胞肺癌诊断中的临床价值[J]. 安徽医科大学学报, 2018, 53(9): 126-129.
    郭良苏. 紫杉醇对非小细胞肺癌患者血清TNF-α和MMPs的影响[J]. 实用临床医药杂志, 2016, 20(03): 137-139.
    陈六生, 吴小红. 血清Pro-GRP、CEA、CA199及Cyfra21-1联合检测在肺癌诊断中的临床价值[J]. 临床合理用药杂志, 2020, 13(11): 160-161.
    杨玲. 非小细胞肺癌患者血清中CD8+T细胞、CEA及CA199水平与肿瘤转移的相关性分析[J]. 江西医药, 2020, 55(02): 218-221.
    杜军华, 乔洪源, 尹宜发, 等. 血清CEA、CA125及Cyfra21-1水平对中晚期非小细胞肺癌患者预后的影响[J]. 肿瘤防治研究, 2016, 43(2): 137-140.
    邓建林, 钟久鸿. 热疗联合培美曲塞及顺铂对中晚期肺腺癌患者CYFRA21-1、CA199、TPS的影响[J]. 临床肺科杂志, 2020, 25(01): 117-121.
    陈恩田, 夏丹. 重组人血管内皮抑制素联合特罗凯治疗一线化疗失败的晚期非小细胞肺癌的临床疗效[J]. 实用癌症杂志, 2019, 34(9): 1553-1556.
    谭兴平, 刘娜娜, 付愚, 等. 吉西他滨联合顺铂对晚期非小细胞肺癌患者生存质量、预后及血清CYFRA21-1、IGF-1水平的影响[J]. 中国老年学杂志, 2018, 38(8): 1835-1837.
    李冬玲, 刘寿芳, 尹光凤, 李晓非, 李松鹏. 血清ProGRP、CEA、CYFRA211、NSE、CA199和AFP联合检测在肺癌诊断的临床价值[J]. 中华临床实验室管理电子杂志, 2019, 7(03): 145-149.
    罗俐梅, 罗娅, 蔡宜含, 冯伟华, 蔡蓓. 外周血淋巴细胞绝对计数在结直肠癌和食管癌肿瘤进展与治疗前后免疫状态评估的临床应用研究[J]. 中华临床实验室管理电子杂志, 2019, 7(03): 137-144.
    • Related Articles

  • Related Articles

    [1]ZHANG Shuyuan, HUANG Yongtao, YU Wenjin. Relationship between non-high-density lipoprotein cholesterol and cardiovascular disease in maintenance hemodialysis patients[J]. Journal of Clinical Medicine in Practice, 2025, 29(5): 106-111. DOI: 10.7619/jcmp.20244504
    [2]MAO Juncong, HONG Yunfei, WEI Yin, CAI Yerui, YIN Jinsong. Application values of triglyceride and glucose index, metabolic insulin resistance score and triglyceride to high-density lipoprotein cholesterol ratio in patients with acute coronary syndrome complicated with multivessel coronary artery disease[J]. Journal of Clinical Medicine in Practice, 2025, 29(5): 56-63. DOI: 10.7619/jcmp.20243599
    [3]LI Yanian, HE Shenghu. Research progress of triglyceride glucose-body mass index[J]. Journal of Clinical Medicine in Practice, 2022, 26(9): 130-133. DOI: 10.7619/jcmp.20213765
    [4]DENG Junjie, HU Jingxuan, LI Xinghua, LU Yao. Value of small dense low density lipoprotein cholesterol in predicting major adverse cardiovascular events of elderly patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 34-38. DOI: 10.7619/jcmp.20214401
    [5]QIU Xueting, WANG Min, WANG Zhixiao, YANG Tao, SUN Min. Relationship between high density lipoprotein cholesterol level and thyroid autoimmunity[J]. Journal of Clinical Medicine in Practice, 2021, 25(13): 1-4, 14. DOI: 10.7619/jcmp.20211491
    [6]CHEN Yuchi, LIU Qiang. Correlation between monocyte to high-density lipoprotein cholesterol ratio and carotid artery stenosis in patients with acute cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2021, 25(3): 36-39. DOI: 10.7619/jcmp.20201217
    [7]JU Xiangli, PEI Dongmei. Relationship between 25 hydroxyvitamin D deficiency and abnormal blood lipid, overweight or obesity[J]. Journal of Clinical Medicine in Practice, 2020, 24(6): 101-104. DOI: 10.7619/jcmp.202006028
    [8]CHEN Jianbing, CHEN Yinuo, ZHUANG Xiao, FENG Panpan, YANG Fan, WANG Xiang, JI Yue′e, WANG Jinchun. Role of scutellaria baicalensis stem-leaf total flavonoid in regulating blood lipid level of rats with hypertriglyceridemia[J]. Journal of Clinical Medicine in Practice, 2019, 23(21): 70-73. DOI: 10.7619/jcmp.201921021
    [9]SUN Wenjing, HUANG Liuqing, ZHOU Fei, YANG Yang, WANG Huaying, XIE Tao, YOU Chunmei. Value of apolipoprotein B combined with low density lipoprotein cholesterol detection in the predication of acute cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2018, (21): 102-103,106. DOI: 10.7619/jcmp.201821031
    [10]ZHANG Guanzhuang. Correlations between cerebral hemorrhage transformation and total cholesterol, low density lipoprotein and high density lipoprotein[J]. Journal of Clinical Medicine in Practice, 2016, (11): 18-20. DOI: 10.7619/jcmp.201611006

  • Cited by

    Periodical cited type(10)

    1. 赵婷婷，韩玮. 针对性护理对慢性胃溃疡合并高血压患者的效果观察. 贵州医药. 2024(02): 304-305 .
    2. 洪丹妮，叶艳. 电子病床倾斜角度对消化内科患者舒适度的影响. 医疗装备. 2024(05): 118-120 .
    3. 杨照平. 云南白药辅治脑出血后应激性胃溃疡临床观察. 实用中医药杂志. 2024(06): 1096-1099 .
    4. 段小兵，王国涛，王冠军，胡国超. 血清高迁移率族蛋白Bl、白细胞介素-6与高血压性脑出血患者神经内镜微创术后神经功能及预后的关系. 成都医学院学报. 2024(04): 674-678 .
    5. 王攀，曾群. 中老年女性脑出血患者合并胃肠功能紊乱的多因素分析预测模型构建. 中国妇幼保健. 2024(20): 4045-4048 .
    6. 刘春军，严方方，杨哲，王宝锋. 瑞巴派特联合莫沙必利治疗应激性胃溃疡的效果分析. 中国实用医刊. 2024(23): 91-93 .
    7. 徐微，林小花，刘媛，何雪云，徐建光. 甘海胃康胶囊联合西药治疗气滞型老年胃溃疡临床研究. 新中医. 2023(17): 112-116 .
    8. 王磊，夏岩，张灯亮. 高血压脑出血患者术后出现消化道应激性溃疡出血的影响因素分析. 现代医学. 2023(10): 1464-1469 .
    9. 巩丹丹，马兴好. 高能量密度肠内营养支持对应激性胃溃疡患者胃粘膜修复的影响. 中国食物与营养. 2022(08): 53-56+62 .
    10. 田永建，姜伟峰，刘芳. 消化内镜联合瑞巴派特在胃溃疡出血中应用价值分析. 疾病监测与控制. 2022(05): 383-386 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML
    Article views (460) PDF downloads (18) Cited by(11)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return